In a previous study on stage II colon cancer patients, the invasive gross tumor type, elevated pre-operative serum CEA level and lack of adjuvant therapy were identified as risk factors for a shorter relapse-free survival (7). This evidence concerns the gene CEACAM5 and malignant colon neoplasm.